CAPhO Conference 2022

Program at a Glance

Jump to date

2022-04-18 April 18, 2022
2022-04-21 April 21, 2022
2022-04-22 April 22, 2022
2022-04-23 April 23, 2022
2022-04-24 April 24, 2022

Notes:
*Program is subject to change. Continue to check the website for updates on topics and presenters.
*To view session descriptions click on "More Info" and then click on the presenter's name to view their biography.
*On-demand symposia are available for viewing as of Monday, April 18. 

Monday
April 18, 2022
All times indicated are Eastern Daylight Times (EDT).

On-demand symposia
Viatris Sponsored On-demand Symposia - Hot Topics in Oncology Biosimilars: Learning from our past to inform and optimize future implementation
Presenters
Lauren (Flay) Charbonneau
Kimberly Kuik
Frank Walsh
Rosemarie Patodia
Photo of Lauren (Flay) Charbonneau
Photo of Lauren (Flay) Charbonneau
Lauren (Flay) Charbonneau
Manager, Pharmacy, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Pharmacy manager at Odette Cancer Centre at Sunnybrook Health Sciences Centre in Toronto, ON. Long time CAPhO and organizing committee member. Oncology pharmacy education is so important to what we do every day.
Lauren (Flay) Charbonneau
Sunnybrook Health Sciences Centre, Toronto, Ontario
Photo of Kimberly Kuik
Photo of Kimberly Kuik
Kimberly Kuik
BScPharm
Pharmacy Professional Practice Leader, Pharmacy, BC Cancer — Victoria, British Columbia
Kimberly Kuik
BC Cancer, Victoria, British Columbia
Frank Walsh
Clinical Pharmacist, Pharmacy, Eastern Health-H. Bliss Murphy Cancer Centre — St. John's, Newfoundland and Labrador
Frank Walsh
Eastern Health-H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador
Rosemarie Patodia
— Toronto, Ontario

BScPhm, BCGP, CDE

Rosemarie Patodia
, Toronto, Ontario

Learning Objectives:
•    Summarize key points about biosimilars that are relevant to their practice and to learn about nuances in practice, from province-to-province
•    Explore best practices, avoidable pitfalls related to biosimilar transitioning
•    Consider how to implement consistent practices with respect to biosimilars in oncology pharmacy, from policy for clinic usage to clinical decision-making
 

On-demand symposia
Pfizer Canada Sponsored On-demand Symposia - Cancer Patient Journey and its Polypharmacy : What to Consider for The Management of Cancer-Associated Thrombosis

Learning Objectives:

  1. Understand the evolution of anti-cancer therapies and the challenges/considerations of polypharmacy throughout the journey of a patient with malignancy
  2. Discuss the potential implications of GI toxicity for drug absorption and drug-drug interactions and the importance of the pharmacist’s role in the selection of anticoagulation for the management of patients with cancer associated thrombosis
  3. Review the latest evidence on bleeding and thrombotic risks when selecting an anticoagulant for the management of patients on anticancer therapies. 

Thursday
April 21, 2022
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
AbbVie Sponsored Symposium- Teaming Up Against Leukemia: A Focus on Patients Living with AML or CLL with Comorbidities or Advanced Age
Presenters
Tina Crosbie
Tammy De Gelder
Photo of Tina Crosbie
Photo of Tina Crosbie
Tina Crosbie
Clinical Pharmacist - Hematology, Pharmacy, The Ottawa Hospital — Ottawa, Ontario
Tina is the clinical pharmacist in the hematology chemotherapy unit at The Ottawa Hospital. Here she oversees patients with lymphomas, multiple myeloma and chronic lymphocytic leukemia who are receiving care on an outpatient basis. Tina joined the hematology team at The Ottawa Hospital in 1999. Tina has written educational materials and has given presentations on topics in hematology and patient care. She enjoys being a peer reviewer for CCCEP, is the current President of CAPhO and serves on the Oncology Fundamental Day (OFD) education committee. Tina was honoured to chair the 2018 CAPhO conference in Ottawa. Tina received her Bachelor of Science in Pharmacy at Memorial University of Newfoundland and completed an accredited residency in hospital pharmacy in Ottawa.
Tina Crosbie
The Ottawa Hospital, Ottawa, Ontario
Photo of Tammy De Gelder
Photo of Tammy De Gelder
Tammy De Gelder
RN(EC), MN, CON©
Nurse Practitioner, Hematology, Hamilton Health Sciences — Hamilton, Ontario

Tammy De Gelder has been practicing nursing for over 25 years. Starting at the bedside in Hematology, she then moved to clinical trials as a coordinator. In 2007 she obtained a Masters in Nurse Practitioning and specialized in myeloid malignancies along with allogeneic stem cell transplantation. Over the years she has put her heart and soul into providing quality patient care and promoting nursing education. Outside of her profession she loves to take long walks, camp, canoe and travel with her husband, kids, family and friends.

Tammy De Gelder
Hamilton Health Sciences, Hamilton, Ontario

Presentation Summary: 

Recent additions to acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) treatment armamentariums created a need for the revision of existing treatment algorithms and protocols for patients ineligible for intensive first-line therapies.  
Several novel approaches include combinations of established agents and new molecules (for example, the addition of venetoclax to azacitidine for the treatment of AML) or improved versions of existing classes of drugs (i.e., the novel BTK inhibitor, acalabrutinib, for the treatment of CLL).  The emerging challenges revolve around integrating novel approaches with what is already in place while considering patient fitness, comorbidities, and treatment-related adverse events.  
Through several case studies, this interactive presentation will explore how pharmacists and nurses are adapting their approaches to patient counselling and monitoring while integrating novel approaches into their practice. 

Leaning Objectives: 

  1. Identify how comorbidities and advanced age can affect tolerance to treatment
  2. Review prevention strategies for treatment-related adverse events such as tumor lysis syndrome (TLS) and infections
  3. Outline therapy options for patients ineligible for intensive first-line treatment in AML and CLL
Satellite symposium
Gilead Sponsored Symposia- The ABCs of ADCs in Breast Cancer
Presenters
Scott Edwards
Sandy Sehdev
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — st john's, Newfoundland and Labrador
Scott Edwards
Eastern Health, st john's, Newfoundland and Labrador
Photo of Sandy Sehdev
Photo of Sandy Sehdev
Sandy Sehdev
Medical Oncologist, The Ottawa Hospital Cancer Centre — Ottawa, Ontario

Sandy Sehdev trained in medical oncology at the University of Toronto and The Princess Margaret Cancer Centre (1991).  

He worked at The William Osler Health System (Toronto) for 25 years (-2016) and while there was Chief of the Pharmacy & Therapeutics Committee, and lead of the clinical trials program (oncology) and continuing medical education (oncology). He was a past lead of CME for the Community Oncologists of Metropolitan Toronto (COMET), and a past Director of the Cancer Advocacy Coalition of Canada.  He is a co-founder of the Physician Alliance for Cancer Care and Treatment (Canada), an oncologist led advocacy coalition, and is a scientific advisor for the Canadian Cancer Survivor Network, and the Canadian Breast Cancer Network. 

He is currently a medical oncologist at The Ottawa Hospital Cancer Centre, focusing on the treatment of breast, prostate cancers and melanoma and lead for the breast cancer disease site.  He was the 2020 winner of the “Golden Throat” teaching award.  
 

Sandy Sehdev
The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Presentation Summary:

Recent clinical developments in breast cancer led to the approval of several antibody-drug conjugates (ADCs), a new class of targeted agents. This symposium aims to strengthen oncology pharmacists’ knowledge and confidence with ADCs.  It will provide an overview on ADC drug development and highlight the similarities and differences including key characteristics and mechanism of action. The speakers will review the impact these targeted therapies will have on clinical practice, patient selection, management and outcomes.  Patient cases will be used to clarify the role of oncology pharmacists in the monitoring and management of key ADC-associated adverse events.    

Learning Objectives:
•    Enhance awareness of how new and future treatment options are impacting the management of patients with breast cancer
•    Understand differences between ADCs and how this potentially impacts clinical management 
•    Increase clarity and confidence with side effect monitoring and management strategies of different ADCs

Satellite symposium
Beigene Sponsored Symposia- BTK Inhibitors for Hematological Malignancies- Practical Considerations for Pharmacists’
Presenters
Anthony J. Perissinotti
Photo of Anthony J. Perissinotti
Photo of Anthony J. Perissinotti
Anthony J. Perissinotti
PharmD, BCOP
— Ann Arbor, Michigan

Anthony J. Perissinotti, PharmD, BCOP, is a hematology clinical pharmacist specialist at the University of Michigan – Michigan Medicine, clinical team leader of hematology/oncology, and adjunct clinical assistant professor at the University of Michigan College of Pharmacy in Ann Arbor, Michigan. Dr Perissinotti obtained his Doctor of Pharmacy degree from Wayne State University in Detroit, Michigan. He completed his first year of postgraduate residency at the Detroit Medical Center – Harper University Hospital in Detroit, and he completed his second year of postgraduate residency training at The University of Texas MD Anderson Cancer Center in Houston. Dr Perissinotti is a board-certified hematology/oncology pharmacist.

Anthony J. Perissinotti
, Ann Arbor, Michigan

Presentation Summary:

Treatment strategies for patients with mature B-cell malignancies are rapidly transitioning away from cytotoxic chemotherapy toward oral targeted therapies.  While newer and better tolerated targeted therapies (BTK inhibitors) are now available, it can be challenging to stay current on emerging data, which can act as a barrier to adoption. Additionally, there is an initial learning curve for clinicians on how to monitor, prevent, and manage adverse events associated with BTK inhibitors. This program is intended to fill these knowledge gaps.

Learning Objectives: 

  1. Review the current indication of the 3 BTKi currently on the market
  2. Discuss the main dosing information, warnings & precautions, and interactions with BTKis
  3. Review the management of most common AEs associated with BTKi
  4. Key management & follow up considerations for patients on BTKis
  5. Pharmacist’s Advice to patients on BTKis

Friday
April 22, 2022
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Jazz Pharmaceuticals Sponsored Symposia- Advances in Frontline AML Treatment with a Focus on Optimizing Care During Intensive Induction
Presenters
Rami El-Sharkawy
Photo of Rami El-Sharkawy
Photo of Rami El-Sharkawy
Rami El-Sharkawy
RPh, BSc (Pharm), PhD(c)
Hematology and Stem Cell Transplant Clinical Pharmacist, Juravinski Hospital and Cancer Centre — Hamilton, Ontario

Rami is a clinical pharmacist caring for adult malignant hematology patients, including acute leukemia, stem cell transplant and cellular therapy.  He received his pharmacy degree from Alexandria University in Egypt, and currently practices at the Juravinski Hospital and Cancer Centre in Hamilton, Ontario.

Rami El-Sharkawy
Juravinski Hospital and Cancer Centre, Hamilton, Ontario

Presentation Summary:

After nearly 50 years of continuous-infusion cytarabine with an anthracycline (“7+3”) as the mainstay of induction chemotherapy for acute myeloid leukemia (AML), several new agents have been recently approved by Health Canada for this heterogenous hematologic malignancy.  This presentation will provide an overview of some of the newly approved frontline AML treatments, followed by a discussion on supportive pharmaceutical care during intensive induction.

Learning Objectives: 

  1. Outline key efficacy and safety data of newly approved frontline AML treatment options
  2. Review the common classes of supportive medications used during intensive induction for AML
  3. Discuss the rationale and timing of antimicrobial prophylaxis for severe neutropenia
  4. Describe the mechanisms of selected drug-drug interactions and management strategies
Satellite symposium
Ipsen Biopharmaceuticals Sponsored Symposium- Managing Oral VEGF Inhibitors to Achieve Optimal Patient Outcomes: What is the Role of the Oncology Pharmacist?
Presenters
Glenn Myers
Scott Edwards
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
BScPharm, ACPR, RPh
Clinical Pharmacist - Outpatient Medical Oncology, Pharmacy, Horizon Health Network / OncoPharm Consulting Inc. — Moncton, New Brunswick
Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and an Accredited Canadian Pharmacy Resident (ACPR) certificate at the Saint John Regional Hospital in 2011-12. He has been working in ambulatory medical oncology for 10 years and focuses his clinical interventions on the collaborative assessment and management of chemotherapy, oral anti-cancer and immune related adverse events. Glenn's research efforts focus on ambulatory practice based research and enjoys mentoring various levels of pharmacy learners.
Glenn Myers
Horizon Health Network / OncoPharm Consulting Inc., Moncton, New Brunswick
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — st john's, Newfoundland and Labrador
Scott Edwards
Eastern Health, st john's, Newfoundland and Labrador

Presentation Summary:
Oral inhibitors of vascular endothelial growth factor (VEGF) are well established in treatment algorithms for several types of cancer. As newer generation tyrosine kinase inhibitors (TKIs) emerge that may be more potent, it is important to be aware of the drug-induced toxicities that patients may experience while on these therapies and know how to manage them. This symposium will provide an overview of oral VEGF inhibitors, including their mechanisms of action, pharmacokinetics, and adverse event management strategies. The speakers will explore hypothetical patient cases to illustrate the role of oncology pharmacists in managing the dosing of oral VEGF inhibitors to manage toxicity and achieve optimal patient outcomes.

Learning Objectives:

  1. Describe the mechanisms of action and pharmacokinetics of oral VEGF inhibitors
  2. Discuss the role that oncology pharmacists can play in optimizing therapy with oral VEGF inhibitors
  3. Outline tips and tricks for dose adjusting oral VEGF inhibitors and managing toxicity to maintain patients on therapy
Welcome Remarks
Plenary session
Food and Cancer – Associations YES, Causation??
Presenters
James McCormack
Photo of James McCormack
Photo of James McCormack
James McCormack
Professor, Faculty of Pharmaceutical Sciences, University of British Columbia — British Columbia

James is a professor at UBC and teaches in Pharmacy and Medicine. He has had extensive experience, both locally and internationally, talking to health professionals and consumers about the rational use of medication, and has presented over 500 seminars on drug therapy over the last 30 years.

He focuses on shared decision-making using evidence-based information and rational therapeutic principles and he is also the co-host of a very popular weekly podcast called the Best Science (BS) Medicine podcast.

James McCormack
University of British Columbia, British Columbia

Presentation Summary:

In my presentation I will discuss how we figure out if various foods are beneficial or harmful to human health. I will then provide a synopsis of the best available evidence around nutrition and health outcomes in general, with a focus on cancer.

Learning Objectives:

  1. Incorporate best evidence to help inform decision making when it comes to nutrition
  2. Identify the strengths and limitations of the evidence around nutrition
  3. Recognize the responsibility of health professionals to incorporate patient values into the decision-making process when it comes to nutrition
Networking session
Networking
Break
Break amongst the Exhibits and Posters
Concurrent session
Chemoradiotherapy – An Overview of the Modality and Toxicities
Presenters
Mark Pasetka
Mark Pasetka
Oncology Pharmacy - Clinical Practice Lead, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Mark Pasetka
Sunnybrook Health Sciences Centre, Toronto, Ontario

Presentation Summary:

This session will serve as a review of the concepts behind chemoradiotherapy for the management of different cancer types.  In addition, an overview of common toxicities seen in a select number of disease sites and associated treatments will be presented. 

Learning Objectives:

  1. Describe the rationale for the use of chemoradiotherapy in specific cancer sites
  2. Recall the common toxicities associated with specific treatments and cancer sites
  3. Summarize therapeutic approaches to management of toxicities
Concurrent session
Innovative role as a Pharmacy Technician in Clinical Informatics
Presenters
Shelley Dellamattia
Photo of Shelley Dellamattia
Photo of Shelley Dellamattia
Shelley Dellamattia
Clinical Informatics Specialist, BC Cancer – Provincial Pharmacy — British Columbia

Shelley has worked as a pharmacy technician with BC Cancer at various centres for the past 15 years, in many different rolls including purchaser, Clinical Trials technician, and Drug Access Navigator.  She currently works as a Clinical Informatics Specialist for BC Cancer and is involved with the implementation of an enterprise CPOE system in all 6 Centres.  Shelley is a Registered Pharmacy Technician and licensed with the College of Pharmacists of BC.  She always strives to prioritize patient safety.

Shelley Dellamattia
BC Cancer – Provincial Pharmacy, British Columbia

Presentation Summary:

Pharmacy Technicians as Clinical Informatics Specialists: the link between clinical and technology to improve patient outcomes. This presentation will review how a Pharmacy Technician can provide knowledge, support, and advocacy for best medication practice in an electronic clinical information system.

Learning Objectives: 

  1. Describe informatics and how Pharmacy Informatics plays a role in Healthcare. 
  2. Recognize the role of Pharmacy Technicians as Clinical Informatics Specialists (CIS)
  3. Understand oncology-related challenges that a CIS manages on a day-to-day basis. 
Concurrent session
Hot Off The Press: Prostate Cancer Updates Making News
Presenters
Lauren Hutton
Photo of Lauren Hutton
Photo of Lauren Hutton
Lauren Hutton
Clinical Coordinator, Pharmacy, NSH — Halifax, Nova Scotia
Lauren Hutton
NSH, Halifax, Nova Scotia

Presentation Summary:

During this session we will be discussing how the care for patients with prostate cancer is rapidly changing.
The evolving treatment of prostate cancer is seeing available therapies being explored in new disease spaces, ever increasing the options available to a patient given their unique situation. Treatments are being sequenced and combined in new, innovative, and increasingly complex patterns. 
Treatment of prostate cancer is requiring an ever more artful, individualized approach to applying applicable evidence, for both anticancer treatment and associated supportive care.

Learning Objectives:  

  1. Answer a patients questions regarding emerging options for chemical androgen deprivation
  2. Apply aspects of the Canadian Urology Association Best Practice Guidelines on Bone Health to your patient care practice
  3. Develop an initial treatment plan for a patient with metastatic hormone sensitive prostate cancer
  4. Summarize the role of immunotherapy in the management of prostate cancer
Concurrent session
Evidence-based Disruption in Supportive Care Delivery
Presenters
Lee Dupuis
Photo of Lee Dupuis
Photo of Lee Dupuis
Lee Dupuis
RPh, FCSHP, PhD
Senior Associate Scientist, Research Institute, The Hospital for Sick Children — Toronto, Ontario

Lee completed BSc, BScPhm and MScPhm degrees at the University of Toronto, a pharmacy residency at Sunnybrook Health Sciences Centre and a PhD at the University of Amsterdam.  She is an Associate Senior Scientist, Research Institute, Health Clinician Scientist, Department of Pharmacy, and a Clinical Pharmacist, Haematology/Oncology/Blood and Marrow Transplant/Cellular Therapy at SickKids and Associate Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. 

Lee is the Chair of the Supportive Care Committee, Pediatric Oncology Group of Ontario and a member of the Supportive Care Steering Committee and Chair of the Antiemetic sub-Committee, Children’s Oncology group.  She has led and participated in many clinical practice guideline panels and is the founder and co-director of the international Pediatric Oncology Guidelines in Supportive Care (iPOG) Network, an organization that facilitates pediatric supportive care clinical practice guideline implementation internationally. 

Lee’s research is focused on improving the supportive care of children who are receiving cancer treatment or undergoing haematopoietic stem cell transplant/cellular therapy.  Her current research is funded by the CIHR and NIH.  She has led many studies and trials seeking to optimize supportive care by facilitating the communication of symptom severity by children, evaluating interventions to control treatment-related toxicity and clinical practice guideline implementation. 

Lee Dupuis
The Hospital for Sick Children, Toronto, Ontario

Presentation Summary:

Constructive disruption is a willingness to change, adapt, and create new trends and technologies.  Oncology pharmacists are at a crossroads where evidence-based practice demands re-evaluation of our practice focus and how we deliver care. In many practice settings, constructive disruption may be required for this to be realized. The availability of trustworthy clinical practice guidelines to prevent and manage treatment-related toxicity demands that oncology pharmacists deliver evidence-based supportive care.  This care should focus on the supportive care needs articulated and prioritized by patients themselves.

Learning Objectives:

  1. Describe the impact of supportive care on the cancer patient’s experience
  2. Recognize the practice changes required to provide meaningful supportive care
  3. Champion the delivery of evidence-based, patient-centred supportive care
     
Satellite symposium
Takeda Oncology Sponsored Symposium- The Current Utility of Real World Evidence (RWE) In Determining Optimal Patient Outcomes – With Emphasis on Quality of Life (QOL) in NSCLC
Presenters
George Dranitsaris
Nathalie Daaboul
Photo of George Dranitsaris
Photo of George Dranitsaris
George Dranitsaris
B.Sc.Phm., MSc, PhD
Consultant in Biostatistics and Outcomes Research, Professor of Research, Department of Public Health, Falk College, Syracuse University — Syracuse, New York
George Dranitsaris
Syracuse University, Syracuse, New York
Photo of Nathalie Daaboul
Photo of Nathalie Daaboul
Nathalie Daaboul
MD FRCPC
Hematologist-oncologist, Hôpital Charles LeMoyne — Sherbrooke , Quebec

Nathalie Daaboul, MD. FRCPC received her medical degree, followed by her hematology and medical oncology training at Université de Montreal. She continued with a clinical research fellowship in thoracic oncology at the Ottawa Hospital Cancer Center. She is currently practicing at the Centre intégré de cancérologie de la Montérégie, at Charles LeMoyne hospital, with an interest in lung and upper GI cancers. She is also an assistant professor at Université de Sherbrooke.

Nathalie Daaboul
Hôpital Charles LeMoyne, Sherbrooke , Quebec

Presentation Summary:

Dr. Nathalie Daaboul and Dr. George Dranitsaris will discuss the current landscape and framework for the use of Real World Evidence (RWE) in evidence-based decision making. They will discuss how patient preferences around treatment management impact clinical outcomes and quality of life. Looking into the future they will share how the RWE will impact patient treatment and potential HTA submissions.

Learning Objectives: 

  1. To understand the sources of RWE and the methodology used to address selection bias, external validity and variability in clinical practice
  2. To discuss the application of RWE and quality of life assessments in shared medical decision making
  3. To understand the potential use of RWE in terms of label expansion and its role in health technology assessment

Saturday
April 23, 2022
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
AstraZeneca Sponsored Symposium - Pharmacists’ Perspective on Supporting Patients with CLL and HER2+ mBC throughout their Treatment Journey
Presenters
Jonathan Stevens
Glenn Myers
Jonathan Stevens
BScPharm, ACPR
Clinical Pharmacist In Onoclogy, Pharmacy, Horizon Health — Quispamsis, New Brunswick
Jonathan Stevens
Horizon Health, Quispamsis, New Brunswick
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
BScPharm, ACPR, RPh
Clinical Pharmacist - Outpatient Medical Oncology, Pharmacy, Horizon Health Network / OncoPharm Consulting Inc. — Moncton, New Brunswick
Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and an Accredited Canadian Pharmacy Resident (ACPR) certificate at the Saint John Regional Hospital in 2011-12. He has been working in ambulatory medical oncology for 10 years and focuses his clinical interventions on the collaborative assessment and management of chemotherapy, oral anti-cancer and immune related adverse events. Glenn's research efforts focus on ambulatory practice based research and enjoys mentoring various levels of pharmacy learners.
Glenn Myers
Horizon Health Network / OncoPharm Consulting Inc., Moncton, New Brunswick

Presentation Summary:

Facilitated by key clinical leaders in oncology pharmacy, this session summarizes the essential role pharmacists play in supporting and managing patients with chronic lymphocytic leukemia (CLL) and HER2+ metastatic Breast Cancer (mBC) throughout their treatment journey. The presentation will outline the utilization of BTK inhibitors for the treatment of CLL, how to apply key practical considerations for therapeutic management, counselling best practices for adherence, and proactive and reactive management strategies for common adverse events, including cardiotoxicities. The session will then transition to how pharmacists can improve the patient journey through optimizing management of treatment related adverse events associated with drug therapy used in the management of HER2+ mBC.

Learning Objectives: 

Part 1: 

  1. Recognize and understand the role of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) in first-line and relapsed/refractory settings
  2. From the Pharmacist perspective, apply key practical considerations for CLL management with BTK inhibitors
  3. Counsel patients on proactive and reactive management strategies for the most common and serious adverse events associated with BTK inhibitors

Part 2: 

  1. Discuss the most common adverse events associated with antibody-drug conjugates & tyrosine kinase inhibitors 
  2. Recognize the importance of adverse events of “special interest”, including interstitial lung disease/pneumonitis & gastrointestinal events
  3. Describe recommendations for monitoring & management of adverse events
Plenary session
From Patient to Practitioner: My Experience as a Cancer Survivor
Presenters
Luke Boechler
Photo of Luke Boechler
Photo of Luke Boechler
Luke Boechler
Oncology Pharmacist, Pharmacy, Saskatchewan Cancer Agency — Saskatoon, Saskatchewan

Luke Boechler is a 31-year-old cancer survivor and oncology pharmacist at the Saskatoon Cancer Centre in Saskatoon, Saskatchewan. At the age of 19, he was diagnosed with Acute Myeloid Leukemia and received a life-saving allogenic stem cell transplant. This experience inspired him to pursue a career in health care. Less than a year post-transplant, he was accepted into the College of Pharmacy and Nutrition at the University of Saskatchewan. He began his career as community pharmacist, spending five years as a Certified Diabetes Educator before transitioning to oncology.

Luke Boechler
Saskatchewan Cancer Agency, Saskatoon, Saskatchewan

Presentation Summary: 

In this presentation, I discuss my personal experience as a young adult cancer survivor. I was diagnosed with Acute Myeloid Leukemia at the age of 19 and received a life-saving stem cell transplant, which has allowed me to continue writing and telling my story. My journey with cancer inspired me to become a health care professional and has given me a unique perspective that influences how I practice oncology pharmacy today. I share actionable insights that I’ve gained from a patient perspective and discuss what a second chance at life means to me.

Learning Objectives:

  1. Analyze patient case for AML
  2. Understand how my experience has influenced my practice
  3. Identify actions that health care professionals can take to positively impact patient care
  4. Discuss life lessons from the perspective of a cancer survivor
Networking session
Networking
Annual General Meeting (AGM)
Break
Break amongst the Exhibits and Posters
Concurrent session
Beyond the Dispensary – Leading Self
Presenters
Dana Lyons
Photo of Dana Lyons
Photo of Dana Lyons
Dana Lyons
RPhT LSS BB
Technical Practice Manager, Pharmacy Services, Provincial Operations, Alberta Health Services — Calgary, Alberta

Dana Lyons is a regulated pharmacy technician, certified lean six sigma black belt and prosci change management professional. Dana’s primary focus is facilitating and leading successful change in pharmacy practice through multi-disciplinary pharmacy teams, using lean and change management methods. Dana’s expertise is in compounding and application of compounding standards. Dana has dedicated much of her career to improving compounding processes, practices and mentoring others to successfully achieve quality processes in their pharmacy environment. Dana is past-President of the Alberta College of Pharmacy. Her passion for pharmacy and contributing back to the profession is something she enjoys.

Dana Lyons
Alberta Health Services, Calgary, Alberta

Presentation Summary:

This presentation will describe the journey of a pharmacy technician career pathway, offering insights and guidance to other pharmacy technicians who may be interested in a joyful career pathway with lasting impact on the profession and patient care.  Together, we will learn how to engage in the profession, for personal and professional growth and how self-leadership is a reflective process. By the end of this presentation, pharmacy technicians will be inspired to lead by example, lead through challenging times, and learn how personal development is an intentional process. 

Learning Objectives:

  1. Identify the importance of engaging within the profession
  2. Recognized how continuous self-improvement can grow you as a professional
  3. Demonstrate ways to develop themselves as leaders of self
  4. Understand and demonstrate self-reflection as a leadership strategy
Concurrent session
The Emergence of Therapeutic Psychedelics in Palliative Oncology
Presenters
Chris Ralph
Photo of Chris Ralph
Photo of Chris Ralph
Chris Ralph
Clinical Pharmacist, Palliative Oncology, Complex Cancer Management Service, Tom Baker Cancer Centre — Calgary, Alberta

Chris Ralph is a clinical pharmacist with the Complex Cancer Management Service, an outpatient palliative oncology multidisciplinary team, at the Tom Baker Cancer Centre in Calgary. Chris has spoken at several regional, national, and international conferences over the years, and has co-authored a chapter in a palliative text published by Oxford University Press. Chris is a graduate of Memorial University of Newfoundland’s School of Pharmacy and a Fellow of CAPhO. Chris is especially curious about therapeutic use of psychedelics and medicinal cannabis, the placebo response, and nature as therapy. In his spare time, you’ll likely find Chris in the Rocky Mountains hiking, biking or skiing; playing guitar or his latest instrument – a Siberian hand-crafted handpan.
 

Chris Ralph
Tom Baker Cancer Centre, Calgary, Alberta

Presentation Summary:

In this presentation, we will explore the emergence of psychedelics as an important therapeutic option in the realm of palliative care in the oncology setting. We will discuss implications and opportunities for oncology pharmacists, with a focus on the hallucinogenic psilocybin, while also briefly discussing the use of ketamine in the palliative oncology setting.  

Learning Objectives: 

Provide an overview of psilocybin therapeutics (and briefly on ketamine) as it pertains to the oncology and palliative care realm with a focus on:
•    Introduction and background to the therapeutic use of psilocybin
•    Current known pharmacology of psilocybin
•    Considerations and limitations of current clinical trial evidence and legal status in Canada
•    Practical considerations for administration and dosing of medicinal psilocybin
•    Theoretical drug interactions
•    Safety and toxicity considerations
•    Potential questions from clinicians and patients

Concurrent session
PracticePrevention.ca - Cancer Prevention & Screening Update
Presenters
Lesley Baldry
Photo of Lesley Baldry
Photo of Lesley Baldry
Lesley Baldry
Health Educator, CancerCare Manitoba Prevention and Screening — Manitoba

Lesley Baldry is a Health Educator with CancerCare Manitoba Prevention & Screening. She develops resources for the public and healthcare providers, and provides education and training to the public, healthcare providers, and staff. While not at work, she enjoys being outside on adventures with her kids.

Lesley Baldry
CancerCare Manitoba Prevention and Screening, Manitoba

Presentation Summary:

While there is a lot in life we cannot control, we can make the best possible daily choices in the areas of cancer prevention and screening to augment our risk of cancer. Join this session to learn how you can PracticePrevention.ca personally and professionally.

Learning Objectives: 

  1. Explain the goal of cancer screening
  2. Identify the eligible population, risk reduction methods, and access points for each screening program
  3. Respond to common questions about cancer prevention and screening
  4. Access more information on cancer prevention and screening
Concurrent session
Factors to Consider When Prescribing Oncology Drugs in Older Adults – Physiology, Interactions, and Deprescribing
Presenters
David Dawe
Photo of David Dawe
Photo of David Dawe
David Dawe
— Winnipeg, Manitoba

Dr. David Dawe is a medical oncologist at CancerCare Manitoba and an assistant professor at the University of Manitoba.  He completed his medical oncology training in Manitoba and treats thoracic cancers. He is the medical lead for CancerCare Manitoba’s initiative focused on improving the experiences and outcomes of older adults with cancer. He leads research focused on investigating treatment patterns and outcomes for frail and older patients with cancer to identify opportunities for system improvement and knowledge translation.

David Dawe
, Winnipeg, Manitoba

Presentation Summary: 

Adults aged 70 years and older account for 45% of cancer diagnoses and have more heterogeneous baseline health than younger patients. Many physiologic changes occur as we age and the number of comorbidities and medications tend to increase. These factors complicate decisions around prescription of oncology drugs, especially oral agents. Physiologic changes can impact dosing and side effects, while polypharmacy increases the risk of drug-drug interactions. These added considerations emphasize the importance of proper drug review and opportunities for deprescribing.

Learning Objectives:

  1. Outline how physiologic changes associated with aging impact the risk profile of oncology drugs
  2. Describe the importance of medication review and assessment for drug-drug interactions
  3. Discuss strategies to increase the chance of deprescribing
Satellite symposium
Apobiologix Sponsored Symposium- Innovation in Oncology Pharmacy in the COVID Era
Presenters
Scott Edwards
Mova Leung
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — st john's, Newfoundland and Labrador
Scott Edwards
Eastern Health, st john's, Newfoundland and Labrador
Mova Leung
Oncology Pharmacy Practitioner, Oncology, North York General Hospital — North York, Ontario
Mova Leung
North York General Hospital, North York, Ontario

Presentation Summary:

This symposium will highlight innovative oncology pharmacy initiatives, starting with the 2022 HOPE Award winning presentations.  Additional highlights will include the use of iMD Health and videos for patient education, AND optimizing virtual 'live' health care professional education through the inaugural Addressing Basics in Cancer (ABC) program.  You won’t want to miss this one of a kind symposium highlighting how innovation has (and will continue to) improve the pharmacy oncology space.

Learning Objectives: 

  1. Best Practices/Key Learnings from the implementation of a digital platform for Oncology Patient Education at North York General Hospital. 2022 update and follow-up on the implementation of the platform during the COVID pandemic
  2. Best Practices/Key Learnings from the implementation of a virtual online learning program for Oncology Pharmacists – The ABC (Addressing the Basics in Cancer) Program 
  3. HOPE Awards Winner Presentations: honour and recognize accomplishments of oncology pharmacists across Canada. The HOPE Awards 2022 2nd annual HOPE (Honouring Oncology Pharmacy Excellence) Awards in Pharmacy. 

Sunday
April 24, 2022
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
BD Sponsored Symposium- Safe to Touch: Implementing an HD Surface Contamination Monitoring Program in a Health System
Presenters
Andre Harvin
Photo of Andre Harvin
Photo of Andre Harvin
Andre Harvin
PharmD, MS, BCPS

Andre Harvin, PharmD, MS, BCPS serves as the Executive Director of Pharmacy, Oncology at Cone Health in Greensboro, NC. In his role he oversees all aspects of Cancer Care for the Cone Health system with a focus on revenue cycle management, managed care, and regulatory. Prior to his current position he has had leadership roles in the Pharmaceutical and PBM industries. He completed his PGY1/PGY2 Health System Pharmacy Administration residency at The Ohio State University and completed his PharmD at University of Michigan.

Andre Harvin

Presentation Summary:

During this symposium, Dr. Andre Harvin will teach the attendees how to apply strategies for implementing safe handling recommendations and hazardous drug (HD) monitoring, identify technologies available and surfaces for monitoring HD contamination, develop an action place for routine monitoring of surfaces for HD contamination and analyze surface monitoring results to identify opportunities for improving HD safe handling. 

Learning Objectives: 

  1. Apply strategies for implementing safe handling recommendations and hazardous drug monitoring
  2. Identify technologies and surfaces that should be used for monitoring HD contamination
  3. Develop an action plan for routine monitoring of surfaces for HD contamination
  4. Analyze surface monitoring results to identify opportunities for improving HD safe handling
Poster Award Presentations
Break
Break amongst the Exhibits and Posters
Round table discussion
Advances in practice: recognizing the expanded role of the oncology pharmacy technician
Presenters
Lily Spasic
Lily Spasic
Clinical Oncology Pharmacist, Pharmacy, Royal Victoria Health Centre — Bolton, Ontario
Lily Spasic
Royal Victoria Health Centre, Bolton, Ontario

This round table will describe current and emerging roles of the oncology pharmacy technician and how this can advance oncology pharmacy practice.

Round table discussion
Exploring IV Workflow Solutions in Oncology
Presenters
Kimberly Kuik
Laura Wilcock
Photo of Kimberly Kuik
Photo of Kimberly Kuik
Kimberly Kuik
BScPharm
Pharmacy Professional Practice Leader, Pharmacy, BC Cancer — Victoria, British Columbia
Kimberly Kuik
BC Cancer, Victoria, British Columbia
Laura Wilcock
Pharmacist, Drcc Pharmacy, Lakeridge Health — Courtice, Ontario
Laura Wilcock
Lakeridge Health, Courtice, Ontario

Review implementation and application of IV workflow solutions in ambulatory oncology settings.  Discuss benefits and challenges to inform your own decision-making. 

 

Round table discussion
Advances in multiple myeloma treatment: a practical perspective
Presenters
Natalie Law
Photo of Natalie Law
Photo of Natalie Law
Natalie Law

Natalie is currently an ambulatory clinic pharmacist at the Princess Margaret Cancer Centre with a focus on multiple myeloma patients. She received her PharmD from the University of Toronto in 2015. She began her career at the Princess Margaret Outpatient Pharmacy and has transitioned to in her current role in 2018.  Her other clinical interests include lymphoma, chronic lymphocytic leukemia, and other plasma cell disorders.  

Natalie Law

In this informal discussion, we will discuss emerging multiple myeloma therapies joining the Canadian landscape. We will explore clinical issues that face oncology pharmacists related to this patient population and share insights on supportive care management.  

Round table discussion
Highlighting Pharmacy’s Role Across Care Transitions for Patients Receiving Take-Home Cancer Drugs
Presenters
Jason Wentzell
Photo of Jason Wentzell
Photo of Jason Wentzell
Jason Wentzell
Extend Pharmacist, Pharmacy, Extend Pharmacy — Ottawa, Ontario
Jason completed his pharmacy degree at Dalhouise University and his Pharmacy Residency at The Ottawa Hospital. He has practiced as an inpatient Medical Oncology pharmacist for nearly 10 years, from 2010 to 2019 and is a Board-Certified Oncology Pharmacist. He has earned a Master’s in Health Management in 2019. Jason is the Founder of and Oncology Pharmacist at Extend Pharmacy, Ottawa’s first cancer-focused ambulatory oncology pharmacy. His areas of research interest include integration of pharmacy learners into practice, simulation education, oral anticancer therapy education and key performance indicators for pharmacists. He is currently involved in several CAPhO initiatives and is a Regional Clinical Coordinator for the University of Waterloo PharmD program in Ottawa.
Jason Wentzell
Extend Pharmacy, Ottawa, Ontario
Networking session
Networking
Plenary session
Practice Changing Articles in Oncology for 2021-2022
Presenters
Scott Edwards
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — st john's, Newfoundland and Labrador
Scott Edwards
Eastern Health, st john's, Newfoundland and Labrador

Presentation Summary: 

Oncology professionals find it difficult to keep up with all the new evidence that is constantly emerging in oncology. This presentation will focus on practice changing articles, breaking down these articles and providing clinical pearls for your practice. These articles will focus on current, evidence-based, practical information which an oncology professional can incorporate into their day-to-day practice. 

Learning Objectives:

  1. Apply takeaways from practice-changing articles of 2021-22
  2. Recognize some of the practical clinical issues from the recent literature.
  3. Demonstrate an understanding of how to apply this new information in daily practice.
Satellite symposium
Emd Serono & Pfizer ULC Sponsored Symposium- UC NOW: A Multidisciplinary Approach to Optimizing the Use of Maintenance Immunotherapy in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Presenters
Bernhard Eigl
Glenn Myers
Michelle Forman
Photo of Bernhard Eigl
Photo of Bernhard Eigl
Bernhard Eigl
MD, FRCPC
Medical Oncologist, BC Cancer Agency — Vancouver, British Columbia

Dr. Eigl is a staff medical oncologist at the Vancouver Cancer Centre and Clinical Associate Professor at the University of British Columbia.  He is the Medical Lead of the Vancouver Centre Clinical Trials Unit.  He is also the Director of the Provincial Clinical Trials Office. The focus of this role is to strengthen and further develop the clinical trial capabilities of all six cancer centers in BC and to improve access to clinical trials for those living with cancer. His clinical areas of expertise are in genitourinary oncology and clinical trials, with a special focus in bladder and prostate cancers where he has held national and international leadership positions on several clinical trials. 

Bernhard Eigl
BC Cancer Agency , Vancouver, British Columbia
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
BScPharm, ACPR, RPh
Clinical Pharmacist - Outpatient Medical Oncology, Pharmacy, Horizon Health Network / OncoPharm Consulting Inc. — Moncton, New Brunswick
Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and an Accredited Canadian Pharmacy Resident (ACPR) certificate at the Saint John Regional Hospital in 2011-12. He has been working in ambulatory medical oncology for 10 years and focuses his clinical interventions on the collaborative assessment and management of chemotherapy, oral anti-cancer and immune related adverse events. Glenn's research efforts focus on ambulatory practice based research and enjoys mentoring various levels of pharmacy learners.
Glenn Myers
Horizon Health Network / OncoPharm Consulting Inc., Moncton, New Brunswick
Photo of Michelle Forman
Photo of Michelle Forman
Michelle Forman
Oncology Nurse, Burnaby Hospital Cancer Centre — Burnaby, British Columbia

Michelle has been working in the outpatient oncology clinic at Burnaby Hospital since 1995, and prior to that had worked in various areas throughout the hospital. Her current role includes administering chemotherapy, patient teaching and management of disease symptoms and treatment side effects. Michelle is passionate about oncology nursing and feels that her knowledge and experience play an integral role in helping to provide for the physical and emotional patient care needs. Michelle has also enjoyed the opportunity to be involved in many projects aiming to enhance the cancer patients experience as well as educating fellow oncology nurses.

Michelle Forman
Burnaby Hospital Cancer Centre , Burnaby, British Columbia

Presentation Summary:

There is a paradigm shift happening in the management of patients with unresectable locally advanced or metastatic urothelial carcinoma (aUC). First-line maintenance immunotherapy for eligible aUC patients has become the new standard of care supported by strong clinical evidence and international guidelines. 

Join a multidisciplinary team of experts to explore the current evidence for maintenance immunotherapy in aUC and discuss the practical aspects of effectively integrating this new therapeutic strategy into clinical practice. Using a case-based approach, faculty members will share their unique perspectives on topics relevant to pharmacists, including patient eligibility, treatment initiation, medication adjustments, toxicity management, and long-term follow-up.

Learning Objectives: 

  1. Summarize the current evidence for maintenance immunotherapy in the first-line treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (aUC).
  2. Interpret specific criteria that make patients with aUC appropriate candidates for first-line maintenance immunotherapy. 
  3. Appraise multidisciplinary perspectives on the effective integration of maintenance immunotherapy into clinical practice, including strategies for patient education, treatment initiation, and adverse event management.